STOCK TITAN

Verona Pharma plc - VRNA STOCK NEWS

Welcome to our dedicated page for Verona Pharma plc news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma plc stock.

Verona Pharma plc (VRNA) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases that have significant unmet medical needs. Headquartered in both the United States and the United Kingdom, Verona Pharma is publicly traded on the NASDAQ Global Market and the London Stock Exchange.

The company's flagship product, Ensifentrine, is currently in development for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Ensifentrine is a dual inhibitor that has demonstrated potential in reducing inflammation and relaxing airway muscles, addressing critical gaps in the treatment of these chronic diseases. In addition to COPD and CF, Verona Pharma aims to expand its therapeutic pipeline to include treatments for other respiratory conditions such as asthma.

Verona Pharma's success is underpinned by a team of seasoned experts with extensive backgrounds in the discovery, development, and commercialization of respiratory therapies. The company has also forged strong partnerships with leading research institutions and advocacy organizations in the respiratory health sector. These collaborations have been instrumental in advancing their clinical programs and have garnered Verona Pharma several awards for innovation.

Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, which showed promising results in improving lung function and reducing symptoms in COPD patients. The company is now steering towards Phase 3 trials, marking a significant milestone in its mission to bring effective treatments to market.

Financially, Verona Pharma has demonstrated stability and growth, strengthening its financial flexibility through strategic funding rounds. This robust financial health supports ongoing research and development activities, ensuring sustained progress in their clinical programs. The company’s near-term goals include advancing Ensifentrine into late-stage clinical trials and exploring potential marketing authorizations.

For the latest updates on Verona Pharma’s research, financial performance, and upcoming milestones, stay tuned to the latest news and press releases.

Rhea-AI Summary

Verona Pharma announced that the FDA has approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adults. Ohtuvayre is the first inhaled treatment in over 20 years offering both bronchodilation and non-steroidal anti-inflammatory effects. The drug is unique as a selective dual inhibitor of PDE3 and PDE4 enzymes and is administered via a standard jet nebulizer.

In clinical trials, Ohtuvayre showed significant benefits when used alone or with other treatments and was well-tolerated by patients with moderate to severe COPD. Verona Pharma plans to launch Ohtuvayre in Q3 2024 through specialized pharmacies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
-
Rhea-AI Summary

Verona Pharma announces its financial results for the first quarter of 2024 and provides a corporate update. The PDUFA Target Action Date for Ensifentrine is set for June 26, 2024, with preparations underway for a potential US launch in the third quarter. The company's strong balance sheet, supported by a recent financing of up to $650 million, is geared towards commercialization and pipeline expansion. Key milestones include launch preparations, COPD disease awareness campaigns, presentations at conferences, and upcoming clinical trials. Financially, cash position remains strong, with R&D expenses and SG&A expenses detailed for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
-
Rhea-AI Summary

Verona Pharma secured $650 million in strategic financing from Oaktree and OMERS to support the US commercial launch of ensifentrine and expand clinical activities. The non-dilutive funding extends the cash runway beyond 2026, providing financial flexibility for growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
Rhea-AI Summary

Verona Pharma plc will present additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for COPD treatment at ATS 2024. The investigational product, ensifentrine, has shown promising results in reducing exacerbations and improving lung function, with potential FDA approval as the first novel inhaled COPD treatment in over 20 years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
conferences clinical trial
-
Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) will report its first quarter 2024 financial results on May 9, 2024, and hold an investment community conference call to discuss the results. The Company encourages participation through dial-in or live webcast, with further details available on their website. Contact information for investor and media inquiries is also provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences earnings
-
Rhea-AI Summary
Verona Pharma plc (VRNA) appoints Mr. Andrew Fisher as General Counsel, bringing extensive legal and strategic experience to the company. Additionally, Ms. Claire Poll retires as General Counsel. Verona Pharma prepares for US commercialization of ensifentrine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
Rhea-AI Summary
Verona Pharma plc announces strong financial results for Q4 and full year 2023, with preparations advancing for the potential launch of ensifentrine for COPD treatment in the US. The FDA has set a PDUFA target action date of June 26, 2024, for ensifentrine, with no advisory committee meeting planned. Verona Pharma secured a $400 million debt financing facility to support commercialization efforts through at least 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Summary
Verona Pharma plc (VRNA) will report its Q4 and full-year 2023 financial results on February 29, 2024. An investment community conference call will follow to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
conferences earnings
-
Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) has announced the appointment of Mr. Michael Austwick as a Non-Executive Director, bringing extensive experience in the biopharmaceutical industry and respiratory expertise. The company also reported the resignation of Mr. Rishi Gupta as a Non-Executive Director. Verona Pharma is preparing for the US launch of ensifentrine, pending approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
conferences

FAQ

What is Verona Pharma plc?

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for respiratory diseases with significant unmet medical needs.

What is Ensifentrine?

Ensifentrine is Verona Pharma's lead therapeutic candidate, currently in development for treating chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).

What diseases does Verona Pharma target?

Verona Pharma targets respiratory diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

Where is Verona Pharma listed?

Verona Pharma is listed on the NASDAQ Global Market under the ticker symbol VRNA and on the London Stock Exchange.

Who leads Verona Pharma?

Verona Pharma is led by a team with deep industry experience, including extensive backgrounds in the discovery, development, and commercialization of respiratory therapies.

What recent achievements has Verona Pharma made?

Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, showing promising results in improving lung function and reducing symptoms in COPD patients.

What are Verona Pharma’s near-term milestones?

The near-term milestones include advancing Ensifentrine into Phase 3 clinical trials and exploring potential marketing authorizations.

Does Verona Pharma have any partnerships?

Yes, Verona Pharma has established relationships with leading research institutions and advocacy organizations in the respiratory health sector.

What awards has Verona Pharma received?

Verona Pharma has received several awards in support of its innovative work in developing therapies for respiratory diseases.

How can I stay updated on Verona Pharma?

You can stay updated on Verona Pharma by following the latest news and press releases on their official website or stock market updates.

Verona Pharma plc

Nasdaq:VRNA

VRNA Rankings

VRNA Stock Data

1.86B
600.57M
3.91%
88.01%
9.52%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
LONDON